Muscle Expression of Mutant Androgen Receptor Accounts for Systemic and Motor Neuron Disease Phenotypes in Spinal and Bulbar Muscular Atrophy  by Cortes, Constanza J. et al.
Neuron
ArticleMuscle Expression of Mutant Androgen Receptor
Accounts for Systemic and Motor Neuron Disease
Phenotypes in Spinal and Bulbar Muscular Atrophy
Constanza J. Cortes,1 Shuo-Chien Ling,2,11 Ling T. Guo,3 Gene Hung,4 Taiji Tsunemi,1,12 Linda Ly,1 Seiya Tokunaga,2
Edith Lopez,1 Bryce L. Sopher,5 C. Frank Bennett,4 G. Diane Shelton,3 Don W. Cleveland,2,6
and Albert R. La Spada1,2,6,7,8,9,10,*
1Department of Pediatrics
2Department of Cellular and Molecular Medicine
3Department of Pathology
University of California, San Diego, La Jolla, CA 92093, USA
4Isis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA
5Department of Neurology, University of Washington, Seattle, WA 98195, USA
6Department of Neurosciences
7Division of Biological Sciences
8Institute for Genomic Medicine
9Sanford Consortium for Regenerative Medicine
University of California, San Diego, La Jolla, CA 92093, USA
10Rady Children’s Hospital, San Diego, CA 92123, USA
11Present address: Department of Physiology, Yong Loo Lin School of Medicine, Centre for Translational Medicine, National University of
Singapore, Singapore 117599, Singapore
12Present address: Department of Neurology and Clinical Neurological Sciences, Northwestern University Feinberg School of Medicine,
Chicago, IL 60611, USA
*Correspondence: alaspada@ucsd.edu
http://dx.doi.org/10.1016/j.neuron.2014.03.001SUMMARY
X-linked spinal and bulbar muscular atrophy
(SBMA) is characterized by adult-onset muscle
weakness and lower motor neuron degeneration.
SBMA is caused by CAG-polyglutamine (polyQ)
repeat expansions in the androgen receptor (AR)
gene. Pathological findings include motor neuron
loss, with polyQ-AR accumulation in intranuclear in-
clusions. SBMA patients exhibit myopathic features,
suggesting a role for muscle in disease pathogen-
esis. To determine the contribution of muscle, we
developed a BAC mouse model featuring a floxed
first exon to permit cell-type-specific excision of
human AR121Q. BAC fxAR121 mice develop sys-
temic and neuromuscular phenotypes, including
shortened survival. After validating termination of
AR121 expression and full rescue with ubiquitous
Cre, we crossed BAC fxAR121 mice with Human
Skeletal Actin-Cre mice. Muscle-specific excision
prevented weight loss, motor phenotypes, muscle
pathology, and motor neuronopathy and dramati-
cally extended survival. Our results reveal a crucial
role for muscle expression of polyQ-AR in SBMA
and suggest muscle-directed therapies as effective
treatments.INTRODUCTION
X-linked spinal and bulbar muscular atrophy (SBMA, Kennedy’s
disease) is an inherited neuromuscular disorder characterized
by adult onset proximal muscle weakness due to lower
motor neuron degeneration. SBMA patients also display signs
of androgen insensitivity, including gynecomastia, reduced
fertility, and testicular atrophy (Katsuno et al., 2012). This
finding, together with the X-linked inheritance, led to analysis
of the androgen receptor (AR) gene as the potential cause of
SBMA. While a CAG repeat in the first exon of the AR gene
varies in length from 5–34 triplets in normal individuals,
SBMA patients were found to harbor repeats ranging from
37–66 CAG repeats (La Spada et al., 1991). As CAG encodes
the amino acid glutamine (Q), SBMA was the first disorder iden-
tified to result from expansion of a CAG-polyQ repeat tract.
Eight other inherited neurodegenerative disorders were subse-
quently found to be caused by expanded CAG repeats; hence,
in addition to SBMA, the CAG-polyQ repeat disease category
includes Huntington’s disease (HD), dentatorubral pallidoluy-
sian atrophy (DRPLA), and six forms of spinocerebellar ataxia:
SCA1, SCA2, SCA3, SCA6, SCA7, and SCA17 (La Spada and
Taylor, 2010).
For decades, research into the basis of neurological disease
focused upon the contribution of neuronal dysfunction to dis-
ease pathogenesis. However, over the last 15 years, there has
been a growing appreciation of the importance of nonneuro-
nal cells in maintaining neuron function and contributing toNeuron 82, 295–307, April 16, 2014 ª2014 Elsevier Inc. 295
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Absence of Mutant AR in Muscle Rescues SBMA Miceneurological disease pathogenesis (Garden and La Spada,
2012). In amyotrophic lateral sclerosis (ALS), the inability to reca-
pitulate SOD1 neurotoxicity in transgenic mice upon expression
of mutant SOD1 in motor neurons argued against cell autono-
mous degeneration (Lino et al., 2002; Pramatarova et al.,
2001). Chimeric expression of mutant and normal SOD1 in the
spinal cords of mice demonstrated a role for nonneuronal cells
in ALS motor neuron degeneration and revealed that astrocytes
andmicroglia are key determinants of disease onset and disease
progression (Clement et al., 2003). Subsequently, conditional
gene silencing of the ubiquitously expressed SOD1 mutant
within astrocytes and microglia indicated that mutant SOD1
within either glial cell type is a key determinant of disease pro-
gression (Boille´e et al., 2006; Yamanaka et al., 2008), while
similar mutant gene silencing in NG2+ precursor cells of oligo-
dendrocytes is a key contributor to disease onset (Kang et al.,
2013). In the CAG-polyQ repeat disease field, careful study of
a line of SCA7 transgenic mice revealed that Purkinje cell neuro-
degeneration occurred even when the polyQ-ataxin-7 transgene
was not expressed in Purkinje cells, leading to a hypothesis of
noncell autonomous SCA7 neurodegeneration (Garden et al.,
2002). As Purkinje cell neurons are intimately associated with
a specialized astroglial cell type known as the Bergmann glia,
SCA7 transgenic mice were engineered to express mutant
ataxin-7 in only Bergmann glial cells in the cerebellum. These an-
imals developed cerebellar ataxia and Purkinje cell degenera-
tion, demonstrating the noncell autonomous nature of polyQ
neurodegeneration (Custer et al., 2006). Studies in HD and in
Parkinson’s disease mouse models have similarly shown that
expression of mutant disease protein in one cell type is capable
of producing dysfunction and demise of a different neuronal cell
type, especially for cells in direct communication with one
another (reviewed in Ilieva et al., 2009). All of this preceding
work suggests an overarching theme in neurodegenerative dis-
ease pathogenesis: preferential degeneration of select neuron
populations does not necessarily stem from intrinsic molecular
pathology restricted to the neuron subtype of interest (i.e., cell
autonomous toxicity), but rather often results from pathological
processes occurring in one or more neighboring cell types that
perform crucial functions upon which the exquisitely vulnerable
neuron subtype stalwartly depends (i.e., noncell autonomous
toxicity).
Skeletal muscle is a major source of trophic support for inner-
vating motor neurons and has been shown to contribute not only
to neuron survival during development, but also to synaptic ac-
tivity and axonal function (Funakoshi et al., 1995). SBMA patients
often exhibit features of myopathy, as progressive muscle weak-
ness occurs in the context of elevated serum creatine kinase
levels (Katsuno et al., 2012). Muscle biopsies of SBMA patients
reveal mixed pathological findings, with both myopathy and
neurogenic atrophy features (Soraru` et al., 2008). Knockin mice
expressing AR with 113 glutamines (AR113Q) develop early
myopathy findings with little or no significant motor neuron loss
until late in their disease course (Yu et al., 2006), consistent
with muscle as a key site for SBMA disease pathogenesis. More-
over, while widespread transgenic expression of human AR20Q
at levels comparable to endogenous AR does not produce a
neuromuscular phenotype (Sopher et al., 2004), skeletal mus-296 Neuron 82, 295–307, April 16, 2014 ª2014 Elsevier Inc.cle-specific overexpression of wild-type AR (AR22Q) in mice
is sufficient to produce SBMA-like neuromuscular disease,
accompanied by denervation of target muscle andmotor neuron
axon degeneration, complete with androgen dependence,
gender bias, axonopathy, and muscle wasting (Monks et al.,
2007). Additionally, testosterone treatment of asymptomatic
female transgenic mice overexpressing the AR22Q transgene
in muscle yielded pronounced neuromuscular deficits, but
without detectable motor neuron pathology (Johansen et al.,
2009). Although development of SBMA-like disease phenotypes
upon skeletal-muscle-specific expression of AR22Q may simply
stem from the very high level of AR transgene overexpression in
this model (Monks et al., 2007), the SBMA-like phenotype in
males can be reversed upon cessation of testosterone treat-
ment. These findings indicate that muscle-restricted AR toxicity
may underlie SBMA disease pathogenesis, and therapies target-
ing skeletal muscle may prove beneficial for patients. In support
of this thesis, transgenic expression of anabolic insulin growth
factor-1 (IGF-1) directed to muscle can rescue nerve pathology
in SBMA transgenic mice, producing a significant extension in
lifespan (Palazzolo et al., 2009).
Although the preceding studies suggest a role for muscle
dysfunction as a component of SBMA motor neuronopathy,
the necessity of polyQ-AR expression in muscle for SBMA dis-
ease pathogenesis is yet to be investigated. To directly examine
the role of muscle expression of AR in SBMA pathogenesis, we
developed a BAC transgenic mouse model featuring a floxed
first exon to permit cell-type-specific excision of the human AR
gene. We engineered the human AR transgene to carry 121
CAG repeats (BAC fxAR121) and found that BAC fxAR121
mice develop a gender-restricted, progressive neuromuscular
phenotype, characterized by weight loss, motor deficits, muscle
atrophy, myopathy, and shortened lifespan. By conditionally
terminating expression of mutant polyQ-AR in the skeletal mus-
cles of BAC fxAR121 male mice, we document a crucial role
for muscle expression of mutant polyQ-AR in SBMA disease
pathogenesis and predict that muscle-directed therapies hold
great promise as definitive treatments for SBMA motor neuron
degeneration.
RESULTS
Generation and Expression Analysis of BAC fxAR121
Transgenic Mice
The human AR gene is composed of eight exons that span180
kb of DNA. Using the Human Genome Browser Gateway (http://
genome.ucsc.edu/cgi-bin/hgGateway), we identified two over-
lapping BACs that span the entire length of theAR gene. Through
a recombineering strategy, we fused these two BACs to create
an AR BAC construct that, in addition to all eight AR exons, in-
cludes 50 kb of DNA 50 to the first AR exon and 30 kb of
DNA 30 to the last AR exon (Sopher and La Spada, 2006). With
this recombineering approach, we also introduced a 121 CAG
repeat tract and engineered two loxP sites flanking AR exon 1
to create a floxed AR CAG121 BAC (BAC fxAR121) transgenic
construct (Figure 1A). We then derived BAC fxAR121 transgenic
mice, and when we performed RT-PCR analysis of human
AR (hAR) transgene expression, we determined that hAR RNA
AB
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Figure 1. Generation and Expression Analysis of BAC fxAR121
Transgenic Mice
(A) Diagram of BAC fxAR121 transgenic construct. After we generated a BAC
containing all eight exons of the human Androgen Receptor (hAR) gene, we
introduced a CAG121 repeat and two loxP sites flanking exon 1.
(B) RT-PCR analysis of cortex, spinal cord, and quadriceps muscle hAR
transgene RNA revealed expression levels that are slightly less than endoge-
nousmouse ARRNA expression levels for BAC fxAR121mice and comparable
to previously published YAC AR100 SBMA mice (Sopher et al., 2004).
(C) Western blot analysis of whole brain protein lysates confirmed expression
of full-length human AR protein (arrowhead, hAR) in the CNS of BAC fxAR121
mice. In this experiment, we used an anti-AR antibody that cross-reacts with
mouse AR protein, which is detected at a lower molecular mass (arrowhead,
mAR). b-actin immunoblotting serves as a loading control.
See also Figure S1.
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fxAR121 mice are comparable to endogenous mouse AR (mAR)
RNA expression levels and to hAR RNA expression levels in AR
YAC CAG100 (YAC AR100) mice (Figure 1B). We measured pro-
tein expression in brain and spinal cord and similarly found that
hAR protein levels in the CNS of the BAC fxAR121mice are com-
parable to mAR endogenous protein levels (Figure 1C) and
to YAC AR100 transgene expression levels (Figure S1 available
online). These are encouraging results, as YAC AR100 micedevelop a highly representative SBMA motor neuronopathy
(Sopher et al., 2004).
Male BAC fxAR121 Mice Display Progressive
Neuromuscular Disease and Premature Death
We then inspected the BAC fxAR121 transgenic mice for visible
phenotypes and behavioral impairments. Beginning at 12 weeks
of age, we observed a significant decrease in the weight of
male BAC fxAR121 mice, and this weight loss phenotype
steadily progressed as the mice aged (Figure 2A). By the
time of significant weight loss, BAC fxAR121 mice exhibited
onset of a motor phenotype characterized by weakness, as
13-week-old male BAC fxAR121 mice displayed significantly
reduced grip strength (Figure 2B). With disease progression,
male BAC fxAR121 mice also exhibited gait abnormalities,
based upon impaired performance on stride length testing
(Figure 2C). Muscle sections from male BAC fxAR121 mice
contained AR protein aggregates (Figure 2D), and NADH stain-
ing of such muscle sections revealed muscle fiber atrophy (Fig-
ure S2A), consistent with an ongoing process of muscle atrophy
due to AR polyQ neurotoxicity, as previously reported in the
YAC AR100 mice (Sopher et al., 2004). When we examined
ventral horn neurons from lumbar spinal cord sections, we did
not observe any changes in motor neuron numbers between
male BAC fxAR121 mice and nontransgenic littermate controls
(Figure S2B), but noted that ventral horn neurons from BAC
fxAR121 mice appear smaller than ventral horn neurons in
nontransgenic littermate controls (Figure 2E). We therefore
measured ventral horn neuron soma size and perimeter in lum-
bar spinal cord sections and documented marked reductions in
neuron soma area and perimeter in BAC fxAR121 mice (Figures
2F and 2G). Although BAC fxAR121 mice develop neuromus-
cular disease phenotypes reminiscent of YAC AR100 mice
(Sopher et al., 2004), the disease phenotype in BAC fxAR121
is more progressive than in the YAC AR100 model, as lifespan
was dramatically shortened in male BAC fxAR121 mice (Fig-
ure 2H). While male BAC fxAR121 mice display prominent
neuromuscular disease and premature death, female BAC
fxAR121 mice appear phenotypically normal on behavioral
testing and do not suffer weight loss or reduced survival (Fig-
ures S2C and S2D).
Ubiquitous Excision of Floxed hAR Transgene Prevents
SBMA Disease Phenotypes in BAC fxAR121-CMV-Cre
Bigenic Mice
To confirm that efficient in vivo excision of the first exon of the
hAR gene and corresponding inactivation of hAR gene expres-
sion in BAC fxAR121 mice were feasible, we crossed BAC
fxAR121 mice with CMV-Cre transgenic mice. In the resulting
BAC fxAR121-CMV-Cre bigenic progeny, excision of transgenic
hAR exon 1, which includes the translational start site, should
occur in all tissues, yielding inactivation of mutant hAR
expression and prevention of neuromuscular disease. RT-PCR
analysis confirmed that BAC fxAR121-CMV-Cre bigenic mice
display markedly reduced hAR RNA expression levels in brain
and muscle (Figure 3A). Furthermore, immunoblot analysis
yielded no detectable hAR protein in brain or spinal cord protein
lysates isolated from BAC fxAR121-CMV-Cre bigenic miceNeuron 82, 295–307, April 16, 2014 ª2014 Elsevier Inc. 297
AD
F G H
E
B C
Figure 2. BAC fxAR121 Transgenic Mice Display Systemic and Neuromuscular Phenotypes
(A) By 12 weeks of age, male BAC fxAR121 mice no longer continue to gain weight, unlike their nontransgenic littermates (n = 6–14/group). ***p < 0.001, t test.
(B) Combined grip strength analysis at 13 weeks of age reveals significant weakness in male BAC fxAR121 mice in comparison to nontransgenic littermate
controls (n = 3/group). Grip strength is given in arbitrary units, with BAC fxAR121 performance set to 1. *p < 0.05, t test.
(C) Measurement of front limb and hindlimb stride length was performed for 20-week-old male BAC fxAR121mice and nontransgenic littermate controls (n = 5–6/
group). Significant decreases in mean stride length were observed for BAC fxAR121 mice in comparison to controls. **p < 0.01, t test.
(D) AR immunostaining of quadriceps muscle sections from 20-week-old male BAC fxAR121 mice and nontransgenic littermate controls reveals focal AR protein
inclusions at the muscle cell periphery in BAC fxAR121 mice. These inclusions appear only occasionally in muscle sections from nontransgenic mice. Scale bar
represents 50 mm.
(E) H&E-stained spinal cord sections from 28-week-old male BAC fxAR121 mice and nontransgenic littermate controls demonstrate that ventral horn neurons in
the lumbar spinal cord are reduced in size in BAC fxAR121 males. Scale bar represents 20 mm.
(F) Quantification of ventral horn neuron soma area shown in (E) (n = 3/group). ***p < 0.001, t test.
(G) Quantification of ventral horn neuron perimeter shown in (E) (n = 3/group). ***p < 0.001, t test.
(H) Kaplan-Meier plot of male BAC fxAR121 mice and nontransgenic littermate controls (n = 9/group) reveals a dramatic reduction in lifespan for BAC fxAR121
mice. p < 0.0001, Log-rank test. Error bars represent SEM.
See also Figure S2.
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Absence of Mutant AR in Muscle Rescues SBMA Mice(Figure 3B), confirming high-level excision of hAR exon 1
and corresponding inactivation of hAR transgene expression.
Phenotype analysis of BAC fxAR121-CMV-Cre bigenic mice
indicated normal weight gain, grip strength, and lifespan (Fig-
ures 3C–3E), thereby validating the utility of the floxed first
hAR exon as a target for Cre-mediated excision and hAR trans-
gene inactivation.
BAC fxAR121-HSA-Cre Bigenic Mice Exhibit Muscle-
Restricted Inactivation of hAR Transgene Expression
To evaluate the contribution of polyQ-AR muscle expression to
SBMA disease phenotypes, we obtained mice carrying the Cre-298 Neuron 82, 295–307, April 16, 2014 ª2014 Elsevier Inc.recombinase gene placed under the control of the Human Skel-
etal Actin (HSA) promoter (Brennan and Hardeman, 1993). The
HSA-Cre mice are known to direct efficient Cre-mediated exci-
sion of floxed transgenes in the skeletal muscle lineage only,
with no ectopic Cre-excision in the spinal cord or in other
CNS regions (Miniou et al., 1999). After crossing BAC fxAR121
mice with HSA-Cre mice, we obtained cohorts of mice with
the following genotypes: BAC fxAR121-HSA-Cre bigenic mice,
BAC fxAR121 singly transgenic mice, HSA-Cre singly trans-
genic mice, and nontransgenic mice. RT-PCR analysis of
RNAs isolated from quadriceps muscle obtained from the
various progeny of this cross revealed marked reductions in
AC
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B Figure 3. Ubiquitous Cre-Mediated Excision
of the Human AR121 Transgene Rescues
Systemic and Neuromuscular Phenotypes in
BAC fxAR121 Mice
(A) We measured hAR transgene expression in
6-week-old male BAC fxAR121-CMV-Cre bigenic
mice in comparison to singly transgenic male BAC
fxAR121 mice (n = 3/group) by quantitative RT-PCR
(qRT-PCR) analysis. We observed marked re-
ductions in hAR transgene expression in the brain
and quadriceps muscle of BAC fxAR121-CMV-Cre
bigenic mice. Results are normalized to hAR trans-
gene expression in BAC fxAR121 brain, which was
set to 1. ***p < 0.001, *p < 0.05, t test.
(B) Western blot analysis of cortex and spinal cord
for 6-week-old male BAC fxAR121-CMV-Cre bi-
genic mice and littermate male BAC fxAR121 mice
indicates that hAR protein expression is no longer
detectable in BAC fxAR121-CMV-Cre bigenic mice,
when immunoblotted with human-specific anti-AR
antibody. The first lane contains protein isolated
from HEK293 cells transfected with a hAR125Q
expression construct, and YAC AR100 protein ly-
sates are included as an additional positive control.
b-actin immunoblotting serves as a loading control.
(C) Ubiquitous Cre expression in BAC fxAR121mice
rescues weight loss in 16-week-old male BAC
fxAR121-CMV-Cre bigenic mice (n = 4–10/group).
**p < 0.01, ANOVA with post hoc Tukey test.
(D) Ubiquitous Cre expression in BAC fxAR121mice
rescues grip strength in 13-week-old BAC fxAR121-
CMV-Cre bigenic mice (n = 4/group). Grip strength
is given in arbitrary units, with BAC fxAR121 per-
formance set to 1. *p < 0.05, ANOVA with post hoc
Tukey test.
(E) Kaplan-Meier plot of male BAC fxAR121 mice
and male BAC fxAR121-CMV-Cre bigenic mice
(n = 9/group) reveals significantly extended lifespan
in BAC fxAR121-CMV-Cre mice. p < 0.0001, Log-
rank test. BAC fxAR121-CMV-Cre bigenic mice are
still alive and well beyond 24 months of age. Error
bars represent SEM.
Neuron
Absence of Mutant AR in Muscle Rescues SBMA Micethe level of hAR transgene expression in BAC fxAR121-HSA-
Cre bigenic mice in comparison to BAC fxAR121 singly trans-
genic mice (Figure 4A). Immunoblot analysis corroborated the
RNA expression data, as we observed minimal amounts of
hAR121Q protein in muscle samples obtained from BAC
fxAR121-HSA-Cre bigenic mice (Figures 4B and 4C). AR immu-
nostaining of quadriceps muscle sections independently
confirmed a dramatic reduction in AR protein aggregates in
BAC fxAR121-HSA-Cre mice (Figure 4D). To assure the speci-
ficity of muscle excision by the HSA-Cre driver, we obtained
RNA and protein lysates from spinal cord and noted that hAR
transgene RNA expression levels and hAR121Q protein levels
are similar in the CNS of BAC fxAR121-HSA-Cre mice and
BAC fxAR121 singly transgenic mice (Figures 4E–4G). These re-
sults confirmed muscle-restricted excision of the hAR transgene
in BAC fxAR121-HSA-Cre bigenic mice, indicating that BAC
fxAR121-HSA-Cre mice can be used to assess the role of mus-
cle expression of polyQ-AR in SBMA neuromuscular disease
and cellular pathology. Furthermore, Cre recombinase expres-
sion in skeletal muscle and the accompanying marked reduc-tion of hAR transgene expression in BAC fxAR121-HSA-Cre
mice did not alter expression of endogenous mouse AR in the
muscle, brain, or spinal cord of BAC fxAR121-HSA-Cre bigenic
mice (Figure S3).
Inactivation of hAR Transgene Expression in Muscle
Prevents SBMA Disease Phenotypes and
Neuromuscular Pathology without Reducing AR Protein
Aggregation in the CNS
To determine the role of polyQ-AR muscle expression in SBMA
disease pathogenesis, we performed a thorough phenotyping
analysis on BAC fxAR121-HSA-Cre bigenic mice, BAC
fxAR121 singly transgenic mice, and nontransgenic controls.
Elimination of AR expression in muscle prevented weight loss
in BAC fxAR121-HSA-Cre bigenic mice (Figure 5A). We also
documented normal motor phenotypes in BAC fxAR121-HSA-
Cre mice, as BAC fxAR121-HSA-Cre mice displayed signifi-
cantly improved grip strength, gait performance, and front limb
stride length, in comparison to singly transgenic BAC fxAR121
mice (Figures 5B–5D). Indeed, for all tested measures, BACNeuron 82, 295–307, April 16, 2014 ª2014 Elsevier Inc. 299
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Figure 4. Muscle-Restricted Inactivation of Human AR Transgene Expression in BAC fxAR121-HSA-Cre mice
(A) We measured hAR transgene expression in quadriceps muscle in male BAC fxAR121-HSA-Cre bigenic mice in comparison to singly transgenic male BAC
fxAR121mice (n = 3/group) by qRT-PCR analysis. We documented amarked reduction in hAR transgene expression in BAC fxAR121-HSA-Cre mice at 12 weeks
and 24 weeks of age. Transgene expression is given in arbitrary units, with BAC fxAR121 set to 1. **p < 0.01, ***p < 0.001, t test.
(B) Western blot analysis of quadriceps muscle for 12-week-old male BAC fxAR121-HSA-Cre bigenic mice and littermate male BAC fxAR121 mice indicates that
hAR protein expression (arrowhead) is extremely reduced inmuscle fromBAC fxAR121-HSA-Cremice, when immunoblotted with anti-AR antibody, which cross-
reacts with mAR protein (arrowhead). b-actin immunoblotting serves as a loading control.
(C) Densitometry quantification of muscle protein immunoblot data shown in (B), n = 4 separate experiments. ***p < 0.001, t test.
(D) AR immunostaining of quadriceps muscle sections from 28-week-old male BAC fxAR121 mice, BAC fxAR121-HSA-Cre mice, and nontransgenic littermate
controls reveals a marked reduction in AR protein inclusions at the muscle cell periphery in BAC fxAR121-HSA-Cre mice. Scale bar represents 50 mm.
(E) We measured hAR transgene expression in spinal cord from 12-week-old male BAC fxAR121-HSA-Cre bigenic mice and BAC fxAR121 mice (n = 3/
group) by qRT-PCR analysis and observed similar hAR expression levels. p = n.s., t test. Transgene expression is given in arbitrary units, with BAC fxAR121
set to 1.
(F) Western blot analysis of spinal cord for 12-week-old male BAC fxAR121-HSA-Cre bigenic mice and littermate male BAC fxAR121 mice indicates that hAR
protein expression (arrowhead) is not reduced, relative to mouse AR protein expression (arrowhead) in BAC fxAR121-HSA-Cre mice, when immunoblotted with
anti-AR antibody, which cross-reacts with mouse AR protein. b-actin immunoblotting serves as a loading control.
(G) Densitometry quantification of spinal cord protein immunoblot data shown in (F), n = 4 separate experiments. p = n.s., t test. Error bars represent SEM.
See also Figure S3.
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Absence of Mutant AR in Muscle Rescues SBMA MicefxAR121-HSA-Cre bigenic mice performed comparably to non-
transgenic controls. Lastly, although BAC fxAR121 mice had
reduced survival, there was not a single instance of prema-
ture death in the BAC fxAR121-HSA-Cre cohort (Figure 5E).
Indeed, all BAC fxAR121-HSA-Cre mice were still alive beyond
16 months of age, without visible phenotypes or evidence of
muscle weakness.
After completing behavioral paradigms for testing motor func-
tion, we considered the role of muscle expression of polyQ-AR
protein in SBMA-associated neuromuscular disease pathology.300 Neuron 82, 295–307, April 16, 2014 ª2014 Elsevier Inc.Staining of muscle sections with hematoxylin and eosin revealed
marked muscle fiber atrophy and increased connective tissue in
BAC fxAR121 mice compared to age-matched controls, and
NADH staining demonstrated considerable areas of muscle fiber
atrophy in BAC fxAR121 mice (Figure 6A). Evidence of neuro-
muscular pathology in BAC fxAR121-HSA-Cre bigenic mice,
however, was minimal and limited (Figure 6A), consistent with
a predominant role for polyQ-AR muscle expression in SBMA
neuromuscular disease. To further characterize the extent of
motor neuronopathy in the BAC fxAR121 mice and the role of
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Figure 5. Cre-Mediated Excision of the Hu-
man AR121 Transgene from Skeletal Muscle
Rescues Systemic and Neuromuscular Phe-
notypes in BAC fxAR121 Mice
(A) Cre expression in skeletal muscle rescues
weight loss in 20-week-old male BAC fxAR121mice
(n = 5–10/group). **p < 0.01, ANOVA with post hoc
Tukey test.
(B) Cre expression in skeletal muscle rescues grip
strength in 20-week-old male BAC fxAR121 mice
(n = 5–10/group). Grip strength is given in arbitrary
units, with BAC fxAR121 performance set to 1. **p <
0.01, ANOVA with post hoc Tukey test.
(C) Footprint analysis of 20-week-old male BAC
fxAR121 mice, BAC fxAR121-HSA-Cre mice, and
littermate nontransgenic controls reveal normal
stride in nontransgenic individuals (right), but obvi-
ously shortened strides in BAC fxAR121 mice (left).
The stride of BAC fxAR121-HSA-Cre mice is visibly
improved (middle), more closely resembling the
performance of nontransgenic mice. Fore paw
prints are green, and hind paw prints are blue.
(D) Quantification of stride length analysis shown in
(C), (n = 6–8/group). *p < 0.05, ANOVA with post hoc
Tukey test, front limb. *p < 0.05, ANOVA with post
hoc Tukey test, hindlimb: non tg versus BAC
fxAR121, p < 0.05. BAC fxAR121-HSA-Cre versus
BAC fxAR121, p = n.s.
(E) Kaplan-Meier plot of male BAC fxAR121 mice,
male BAC fxAR121-HSA-Cre bigenic mice, and
male nontransgenic littermates (n = 9–13/group)
reveals significantly extended lifespan in BAC
fxAR121-HSA-Cre mice. p < 0.0001, Log-rank test.
BAC fxAR121-HSA-Cre bigenic mice are still alive
and well beyond 16 months of age. Error bars
represent SEM.
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Absence of Mutant AR in Muscle Rescues SBMA MicepolyQ-AR muscle expression in the production of this pheno-
type, we compared ventral horn regions of lumbar spinal cord
sections obtained from BAC fxAR121 mice, BAC fxAR121-
HSA-Cre mice, and nontransgenic littermate controls. We noted
that ventral horn neurons from BAC fxAR121 mice are reduced
in size, but that ventral horn neurons in BAC fxAR121-HSA-
Cre mice appear comparable to controls (Figure 6B). Quantifica-
tion of ventral horn neuron soma size and perimeter indicated
that excision of mutant AR transgene expression in skeletal
muscle was sufficient to completely rescue this motor neuron
degeneration phenotype in BAC fxAR121-HSA-Cre mice (Fig-
ure 6C). RT-PCR analysis and immunoblot analysis of BAC
fxAR121-HSA-Cre brain RNA and protein samples confirmed
that skeletal muscle excision of hAR transgene expression in
BAC fxAR121 mice does not reduce the level of hAR transgene
expression in the brain (Figures S4A and S4B), as expected.
Moreover, despite rescuing spinal cord neurodegeneration,
excision of hAR transgene expression in muscle did not result
in an appreciable reduction in AR nuclear inclusion formation inNeuron 82, 295–frontal cortex neurons of BAC fxAR121-
HSA-Cre mice (Figure 6D), and immuno-
blot analysis of brain protein lysates from
BAC fxAR121-HSA-Cre mice corrobo-
rated this finding, as insoluble, aggregatedAR protein persists in brain samples from BAC fxAR121-HSA-
Cre mice (Figure S4C).
Excision of hAR Transgene Expression in Skeletal
Muscle PreventsMotor Neuron Axon Pathology in SBMA
Transgenic Mice
To further evaluate the effect of skeletal muscle expression of
mutant AR protein on SBMA motor neuron disease, we gener-
ated sections of spinal cord motor axons from the L5 root and
observed excessive spacing of axons in spinal cord sections
from end-stage BAC fxAR121 mice (Figure 7A). This aberrant
spacing phenotype was absent from L5 root spinal cord motor
axons in littermate BAC fxAR121-HSA-Cre bigenic mice (Fig-
ure 7A). When we measured axon diameters in L5 motor roots
and counted axon numbers based upon diameter, we noted
that BAC fxAR121 mice exhibit a shift toward smaller-sized
axons, but that BAC fxAR121-HSA-Cre mice retain a distribution
of motor axons that is not shifted toward smaller-sized axons
and thus resemble nontransgenic controls (Figure 7B). Indeed,307, April 16, 2014 ª2014 Elsevier Inc. 301
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Figure 6. Excision of Human AR Transgene from Skeletal Muscle Rescues Neuromuscular Pathology without Reducing AR Protein
Aggregate Burden in CNS of BAC fxAR121 Mice
(A) Quadriceps muscle sections from 18-week-old male nontransgenic littermate controls, BAC fxAR121-HSA-Cre mice, and BAC fxAR121 mice were stained
with hematoxylin and eosin (H&E) and NADH. H&E staining of nontransgenic muscle (left) shows normal fibers of similar shape and size, but BAC fxAR121muscle
(right) reveals significant atrophy, with most fibers ofmarkedly reduced caliber. Sections of BAC fxAR121-HSA-Cremuscle (middle) appear relatively normal, with
(legend continued on next page)
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caliber axons (i.e., >9 mm in diameter) in the BAC fxAR121
mice and found that such large caliber axons were not reduced
in L5 roots from BAC fxAR121-HSA-Cre mice (Figure 7C), con-
firming that skeletal muscle excision of hAR transgene expres-
sion can prevent this SBMA motor neuronopathy phenotype in
AR BAC transgenic mice. Importantly, evaluation of L5 motor
roots from younger BAC fxAR121 mice, BAC fxAR121-HSA-
Cre mice, and nontransgenic controls revealed comparable
numbers of motor axons and roughly equivalent numbers of
large caliber axons prior to the onset ofmotor neuronopathy (Fig-
ures S5A and S5B), ruling out developmental variation in motor
axon size selection as the basis for differences in large caliber
axon numbers in older mice.
DISCUSSION
Motor neuron diseases comprise a group of neurodegenerative
disorders characterized by progressive degeneration of motor
neurons, accompanied by muscle weakness and wasting.
Despite decades of research, the mechanistic basis of the
observed motor neuron loss remains enigmatic. Although motor
neuron demise is the cardinal feature of motor neuron disorders,
recent investigations into the cellular basis of disease pathogen-
esis in ALS and autosomal recessive spinal muscular atrophy
(SMA) indicate that the pathogenic cascade is not restricted to
an intrinsic pathological process playing out in the motor neuron
(Bricceno et al., 2012; Ilieva et al., 2009). Rather, considerable
evidence indicates that many motor neuron diseases display
noncell autonomous degeneration, and for SMA, muscle cell
pathology appears to significantly contribute to disease patho-
genesis (Bricceno et al., 2012).
In the case of SBMA, certain features of the disease, together
with previous studies in mouse models, suggested that muscle
might play a key role in this motor neuronopathy (Katsuno
et al., 2012; Palazzolo et al., 2009; Yu et al., 2006); however,
none of these studies definitively addressed whether muscle
expression of the disease-causing polyQ-expanded AR is
required for SBMA neuromuscular phenotypes. Here, we pro-
vide evidence for the necessity of polyQ-AR muscle expression
for the full spectrum of SBMAmotor neuron disease.We find that
excision of a human AR121Q transgene from muscle in BAC
fxAR121 mice prevents the development of both systemic
and neuromuscular SBMA disease phenotypes. Importantly,
we document that BAC fxAR121-HSA-Cre mice retain strong
expression of mutant AR121Q protein in the spinal cord andmost fibers of large caliber, though one area of smaller fibers is present. NADH sta
NADH staining of BAC fxAR121 sections (right) uncovers collections of very dark
occasionally present in BAC fxAR121-HSA-Cre mice (middle). Scale bar represe
(B) H&E-stained spinal cord sections from 28-week-oldmale BAC fxAR121mice, B
ventral horn neurons in the lumbar spinal cord are reduced in size in BAC fxAR121
mice. Scale bar represents 50 mm.
(C) Quantification of ventral horn neuron soma area and perimeter shown in (
represent SEM.
(D) AR immunostaining of frontal cortex from 28-week-old male BAC fxAR121
prominent nuclear inclusions in the cortex of both BAC fxAR121 and BAC fxAR12
dark brown puncta). Scale bar represents 50 mm.
See also Figure S4.brain with continued production of AR protein aggregates,
indicating that CNS expression is not sufficient to yield motor
neuronopathy in SBMA transgenic mice. As BAC fxAR121-
HSA-Cre mice are still healthy without signs of neuromuscular
disease beyond 12 months of age, our findings indicate that
expression of polyQ-AR protein in muscle is a primary driver
of disease pathogenesis and progression in SBMA. Although
the BAC fxAR121 mouse model recapitulates key features of
SBMA disease in human patients, BAC fxAR121 mice do not
exhibit motor neuron loss prior to their demise. Hence, we
cannot completely exclude a role for motor neuron expressed
AR in themotor neuron death occurring in SBMA patients. None-
theless, in a concurrent study, peripheral delivery of an antisense
oligonucleotide (ASO) directed against AR prevented systemic
and neuromuscular phenotypes in two different SBMA mouse
models—BAC fxAR121 and AR113 knockin mice (Lieberman
et al., 2014). As peripheral delivery of anti-AR ASO yielded dra-
matic reductions in polyQ-AR expression in skeletal muscle
but did not produce knockdown of mutant AR gene expression
in the CNS (Lieberman et al., 2014), this work corroborates a
principal role for muscle in SBMA disease pathogenesis.
If muscle expression of polyQ-AR protein is a key site for mo-
tor neuron disease pathogenesis in SBMA, as both this genetic
rescue study and the pharmacological rescue study demon-
strate, could muscle also be a primary site for disease patho-
genesis in related motor neuronopathies? SMA is an autosomal
recessive lower motor neuron disease caused by loss-of-func-
tion mutations in the survival motor neuron (SMN) gene (Lefeb-
vre et al., 1995), and while SMA shares certain features with
SBMA, SMA patients are much more severely affected than
SBMA patients. Numerous lines of investigation indicate that
there are muscle abnormalities in SMA, including deficits in
myoblast fusion, delayed muscle maturation, and onset of
weakness before frank motor neuron loss (Murray et al., 2008;
Mutsaers et al., 2011). Indeed, early studies of SMA in mouse
models confirmed that loss-of-function of SMN protein
restricted to muscle resulted in a severe neuromuscular pheno-
type, most reminiscent of muscular dystrophy (Cifuentes-Diaz
et al., 2001). Furthermore, muscle-specific conditional rescue
in SMA mice yields significant improvement in weight, survival,
and motor behavior, but without any appreciable effect on
synaptic function (Martinez et al., 2012). As gene therapy
approaches relying upon transduction of muscle as a means
to achieve motor neuron delivery simultaneously target muscle,
the beneficial effects of SMN restoration in muscle and in
motor neuron cells in mice have been difficult to separateining of nontransgenic muscle (left) yields occasional dark-staining fibers, while
-staining fibers, undergoing atrophy. Evidence for muscle fiber atrophy is only
nts 50 mm.
AC fxAR121-HSA-Cremice, and nontransgenic littermate controls reveals that
males, and this size reduction phenotype is rescued in BAC fxAR121-HSA-Cre
B), n = 3/group. ***p < 0.001, ANOVA with post hoc Tukey test. Error bars
mice, BAC fxAR121-HSA-Cre mice, and nontransgenic littermates reveals
1-HSA-Cre mice (see inset for AR nuclear aggregates, which are visualized as
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Figure 7. Excision of Human AR Transgene
from Skeletal Muscle Rescues Motor Neuron
Axon Degeneration in BAC fxAR121 Mice
(A) We sectioned L5 spinal cord root motor axons
and observed increased spacing in 28-week-old
male BAC fxAR121 mice (right). No evidence of
axon spacing was present in micrographs from
nontransgenic mice (left) or BAC fxAR121-HSA-Cre
littermates (middle). Scale bars represent 50 mm
(top panel) and 10 mm (bottom panel).
(B) Mean diameters of L5 spinal cord root motor
axons in 28-week-old male nontransgenic mice,
BAC fxAR121-HSA-Cre mice, and BAC fxAR121
mice.
(C) Counting of motor axons revealed a significant
reduction in large caliber (>9 mm diameter) axons in
BAC fxAR121 mice. This phenotype is rescued in
BAC fxAR121-HSA-Cre bigenic mice. **p < 0.01,
ANOVA with post hoc Tukey test: p < 0.01 for BAC
fxAR121-HSA-Cre versus BAC fxAR121, p < 0.05
for nontransgenic versus BAC fxAR121. Error bars
represent SEM.
See also Figure S5.
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Absence of Mutant AR in Muscle Rescues SBMA Mice(Bosch-Marce´ et al., 2011; Martinez et al., 2012). However, pe-
ripheral delivery of an ASO capable of restoring normal levels of
SMN expression, by correcting the SMN2 gene splicing defect,
yielded dramatic rescue of disease phenotypes in SMA mice
and far exceeded the efficacy of CNS-only delivery (Hua et al.,
2011). Although enhanced liver production of IGF-1, which
targets muscle and thereby affects motor neuron health, was
implicated in this peripheral treatment intervention, this result
nonetheless underscores the importance of non-CNS cell
types in SMA disease pathogenesis and highlights the potential304 Neuron 82, 295–307, April 16, 2014 ª2014 Elsevier Inc.importance of muscle as a disease-rele-
vant cell type in SMA (Duan et al., 2010).
The other major motor neuron disease is
ALS, a combined upper motor neuron and
lower motor neuron disorder. Many inves-
tigations into the cellular basis of familial
ALS1 caused by SOD1 mutations have
been performed in SOD1 mouse models,
and these studies have firmly established
that SOD1-mediated disease in ALS1
mice is noncell autonomous, with predom-
inant roles delineated for astrocytes,
microglia, and oligodendrocytes (Boille´e
et al., 2006; Kang et al., 2013; Yamanaka
et al., 2008). However, while overex-
pression of mutant SOD1 within skeletal
muscle can damage it (Dobrowolny et al.,
2008), excision of mutant SOD1 transgene
expression in muscle in SOD1 conditional
mouse models does not produce any
appreciable effect on disease course
(Miller et al., 2006; Towne et al., 2008),
arguing against a primary role for muscle
in ALS1. With the discovery of TDP-43
aggregate pathology in ALS, and subse-quent realization that familial ALS can be caused by mutations
in TDP-43, FUS/TLS, and most frequently GGGGCC repeat ex-
pansions in the C9orf72 gene (DeJesus-Hernandez et al.,
2011; Renton et al., 2011), the cellular basis of ALS disease path-
ogenesis deserves further study. Indeed, recent work on multi-
system proteinopathy pedigrees indicates that accumulation of
misfolded proteins in muscle cells falls within the phenotype
spectrum of observed histopathology in such patients (Benatar
et al., 2013), suggesting that muscle pathology could be contrib-
uting to motor neuronopathy findings in certain cases.
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motor neurons and functionally interfaces with motor neurons at
the neuromuscular junction, where muscle cells receive electri-
cal impulses and modulate electrical activity through postsyn-
aptic regulation (Tabebordbar et al., 2013). If expression of
polyQ-AR protein in skeletal muscle is contributing to SBMAmo-
tor neuron degeneration, then what aspects of muscle dysfunc-
tion promote the disease process? A variety of studies, in both
SBMA patients and mouse models, strongly suggest that loss
of trophic factor support from muscle accounts for SBMA motor
neuron degeneration. Indeed, motor neurons rely upon a number
of growth factors, including vascular endothelial growth factor
(VEGF) and IGF-1, which both can function as neurotrophic fac-
tors. Analysis of YAC AR100 transgenic mice revealed a marked
reduction in the expression of VEGF (Sopher et al., 2004), a neu-
rotrophic factor that, when overexpressed in muscle, can delay
motor neuron disease in SOD1-expressing ALS1 transgenic
mice (Azzouz et al., 2004). IGF-1, another neurotrophic growth
factor shown to promote motor neuron survival in both ALS
and SMA (Bosch-Marce´ et al., 2011; Dobrowolny et al., 2005),
appears to be particularly important in SBMA muscle, as
muscle-directed expression of IGF-1 can rescue systemic and
neuromuscular phenotypes in SBMA mice (Palazzolo et al.,
2009). Other growth factors implicated in SBMA disease patho-
genesis include type II transforming growth factor-b (TGF-b),
glial-derived neurotrophic factor (GDNF), and neurotrophin-4
(Katsuno et al., 2010; Yu et al., 2006). Hence, elimination of
polyQ-AR expression from muscle in BAC fxAR121-HSA-Cre
mice may promote motor neuron survival by restoring the ability
of skeletal muscle cells to produce normal levels of neurotrophic
growth factors and then deliver them to innervating motor
neurons.
Although our discovery of muscle as a crucial site for initiation
of SBMA motor neuron disease illustrates that skeletal muscle
cells and innervating motor neurons are inextricably linked, the
most compelling aspect of this work is its immediate potential
for therapeutic impact. Current therapies for SBMA are aimed
at targeting the mutant AR for degradation or preventing its full
activation (Katsuno et al., 2012), and these approaches are
fraught with potential for side effects. Of the most attractive
therapeutic options available for patients with SBMA or pa-
tients suffering from related neurodegenerative proteinopathies,
dosage reduction shows the greatest promise and is typically
achieved via targeting the disease-causing RNA transcript for
destruction or translation repression (La Spada, 2009). For
SBMA, the prospect of targeting the AR gene in the CNS, though
feasible, could be problematic, as reduced AR action in the CNS
is associated with malaise, lack of focus, listlessness, and loss of
libido upon pharmacological castration (Tammela, 2012). If pe-
ripheral ASO delivery, targeting muscle, offers the potential for
stemming SBMAmotor neuron degeneration, muscle weakness,
and muscle atrophy, this would represent a dramatic paradigm
shift for SBMA therapeutics. While the utility of peripheral ther-
apy directed to muscle for related motor neuron diseases such
as SMA and ALS remains controversial, further development of
peripheral delivery strategies for these disorders may deserve
consideration. Indeed, even neurodegenerative proteinopathies
such as HDmight benefit from peripheral dosage reduction ther-apies, as such disorders involve non-CNS metabolic pathology
(Mochel et al., 2007), and in the case of PD, may stem from the
production of misfolded protein species that form in the enteric
nervous system and then propagate to the CNS (Wakabayashi
et al., 1989). As therapies directed at knocking down disease-
associated genes in the periphery are less invasive and thus
potentially much safer than treatments requiring CNS delivery,
our findings suggest that peripheral dosage reduction should
be explored as a potential treatment option for neurodegenera-
tive disorders.
EXPERIMENTAL PROCEDURES
Mouse Studies
All animal experiments adhered to NIH guidelines and were approved by
the University of Washington Institutional Animal Care and Use Committee
(IACUC) and UCSD IACUC. Construction of the BAC fxAR121 transgene and
derivation of BAC fxAR121 mice have been described (Sopher and La Spada,
2006). Blinded observers visually inspected all mice for general and neurolog-
ical phenotypes starting at 8 weeks of age and weekly thereafter. Behavioral
testing to evaluate grip length and stride length was performed as described
previously (Sopher et al., 2004). Stride length measurements were obtained
for each animal by a blinded investigator.
RT-PCR Analysis
Total muscle, brain, or spinal cord RNA samples were isolated using the Trizol
method (Life Technologies). Quantification of mRNA was performed using an
Applied Biosystems 7500 Real Time Sequence Detection System with ABI
Assays-on-Demand primers and TaqMan-based probes. ABI TaqMan primer
and probe set designations are available upon request. PGK1 was used as the
internal control to normalize results. Relative expression levels were calculated
via the Standard Curve method (Livak et al., 1995).
Western Blot Analysis
Protein lysates from whole brain, spinal cord, or muscle tissue were prepared
as previously described (Sopher et al., 2004). We loaded 50 mg of homoge-
nized proteins per lane, and after running 3%–8% Tris-Acetate gels (Invitro-
gen), samples were transferred to PVDF membranes (Millipore), which were
blocked in 5% milk in PBS at RT for 1 hr. Membranes were incubated with
an anti-AR antibody (H280, sc-13062; AR441, Abcam) or b-actin (ab8226,
Abcam) in PBS-T with 3% BSA at 4C overnight. The primary antibody was
visualized with horseradish-peroxidase conjugated anti-rabbit or anti-mouse
IgG (Santa Cruz) at 1:5,000 dilution and enhanced chemiluminescence (Amer-
sham). Densitometry analysis for human and mouse AR protein quantification
was performed using the NIH ImageJ software application and normalized to
b-actin signal intensity.
Histopathology Studies
Quadriceps, gastrocnemius, and triceps muscles were collected immediately
after euthanasia and then flash-frozen in isopentane precooled in liquid nitro-
gen and stored at 80C until further processing. Cryostat sections (8 mm in
thickness) were stained or reacted with a standard panel of histochemical
stains and reactions as previously described (Dubowitz and Shewry, 2007).
AR immunostaining was performed as previously described (Sopher et al.,
2004).
For motor neuron counts, serial 20 mm transverse sections of the lumbar
cord (L3–L5) were cut and Nissl stained. A blinded investigator counted the
number of positively stained motor neurons in the ventral horn region on
each section (n R 4 sections/spinal cord). For motor neuron soma size and
perimeter quantification, serial 20 mm transverse sections of the lumbar cord
(L3–L5) were cut and stained with hematoxylin and eosin staining (H&E). A
blinded investigator traced motor neuron soma on lumbar ventral horns on
each section (n R 4 sections/spinal cord). Only polygonal neurons with a
clearly identifiable nucleus were counted (nR 100 motor neurons/genotype).
Motor neuron soma area and perimeter were determined using ImageJNeuron 82, 295–307, April 16, 2014 ª2014 Elsevier Inc. 305
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upon the magnification scale.
Our technique for preparation of semi-thin sections of lumbar level 5 (L5)
roots has been described (Arnold et al., 2013). Briefly, anesthetized mice
were transcardially perfused with PBS, followed by 4% paraformaldehyde in
phosphate buffer for fixation. L5 roots were collected and incubated in 2%
osmium tetroxide in 0.05 M cacodylate buffer. The roots were then washed,
dehydrated, and embedded for sectioning in Epon-Araldite resin (Electron
Microscopy Sciences). After generating 1 mm thick sections, L5 root sections
were stained with 1% toluidine blue for 30 s. Entire roots were imaged and
cross-sectional diameter of each axon was measured with Bioquant software.
Axonal diameters of motor axons from L5 roots were recorded and then sub-
divided into 0.5 mm bins.
Statistical Analysis
All data were prepared for analysis with standard spread sheet software
(Microsoft Excel). Statistical analysis was done using Microsoft Excel, Prism
4.0 (Graph Pad), or the VassarStats website (http://faculty.vassar.edu/lowry/
VassarStats.html). For ANOVA, if statistical significance (p < 0.05) was
achieved, we performed post hoc analysis to account for multiple compari-
sons. The level of significance (a) was always set at 0.05.
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